Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
FEXOFENADINE HYDROCHLORIDE vs PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic symptoms without significant central nervous system penetration.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative. Dextromethorphan is a cough suppressant that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
60 mg orally twice daily or 180 mg orally once daily; maximum 180 mg/day.
For cough and upper respiratory symptoms: 5 mL (containing promethazine hydrochloride 6.25 mg and dextromethorphan hydrobromide 15 mg) orally every 4 to 6 hours, not to exceed 30 mL in 24 hours.
None Documented
None Documented
14.4 hours in healthy adults; prolonged in renal impairment (up to 58 hours in end-stage renal disease) requiring dose adjustment.
Promethazine: 10-19 hours (mean 12 hours). Dextromethorphan: extensive metabolizers (CYP2D6) 3-5 hours; poor metabolizers 20-30 hours. Clinical context: accumulation with repeated dosing, especially in poor metabolizers.
Primarily fecal (80%) with approximately 11% renal excretion of unchanged drug. Biliary excretion contributes to fecal elimination.
Promethazine: primarily hepatic metabolism, renal excretion of metabolites (~70%, <1% unchanged); fecal excretion (20-30%). Dextromethorphan: hepatic metabolism, renal excretion of metabolites and <1% unchanged drug.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic